The numbers come first. ChronicleBio has performed 890 blood draws from 709 patients across Utah, Arizona, Texas, and India in its first year of operation. Its biobank holds over 3,500 tubes of blood. The company has extracted 153 terabytes of data from that blood — three times the 45 terabytes used to train GPT-3.5, a 2022 OpenAI model. To date, the startup has raised $15 million.
The founder is Fidji Simo, who left her role as OpenAI's CEO of AGI Deployment — where she reported directly to CEO Sam Altman — after a seven-year battle with Postural Orthostatic Tachycardia Syndrome, or POTS. Before OpenAI, Simo spent a decade at Meta overseeing the Facebook app, then served as CEO of Instacart, which she took public in 2023, before joining OpenAI in 2025.
Simo co-founded ChronicleBio alongside Rohit Gupta and Rishi Reddy. According to Simo, all three co-founders either have chronic diseases themselves or have a family member with one. Greg Brockman, the OpenAI co-founder and president who took over the bulk of Simo's responsibilities when she departed, has a wife with POTS and two other chronic conditions.
The core thesis is clinical, not speculative. Simo says the pharmaceutical industry's clinical trial failure rate for conditions like POTS stems from a fundamental misclassification problem: a single diagnosis may mask five distinct sub-diseases, each with different underlying biology. A drug that works for one sub-group fails the trial because it is tested on all five simultaneously. 'We have already found five sub-diseases where the biology is really different, despite the symptoms being the same,' Simo told Fortune in her first interview since leaving OpenAI.
ChronicleBio's plan is to map those biological sub-groups to existing drugs and begin testing them on its patient population before the end of the year, then partner with biotech and pharma to develop new treatments.
On August 11, the company will launch a sign-up link for mobile phlebotomy trucks to conduct home blood draws for people with certain chronic diseases. The first 250 participants will receive an in-depth report on their condition at no charge, in exchange for contributing their biological data to ChronicleBio's biobank.
Simo describes chronic conditions as 'becoming a real epidemic,' citing 'hundreds of billions in lost productivity' as the economic backdrop for the market opportunity.
The editorial read is straightforward. This is private capital, personal conviction, and AI-driven data science doing what the administrative state and legacy pharma have not: disaggregating disease populations with enough precision to make drug trials succeed. Simo is not waiting for a federal grant or a regulatory mandate. She is building a biobank, recruiting patients, and moving toward trials — all on a $15 million raise. That is free enterprise applied to a problem that costs the economy hundreds of billions of dollars and costs individual patients their quality of life. The market will decide whether the biology holds up. But the model — founder-led, data-first, privately funded — is exactly the kind of structure that produces results when bureaucracy cannot.
